Not exact matches
«This research has broad impact, because by deepening our understanding of
cell reprogramming we have the potential to improve disease modeling and the generation of better sources of patient -
specific specialized
cells suitable for
replacement therapy,» said Plath.
Parkinson contends that targeted gene
replacement produces
cells having
specific genetic alterations far more effectively than the traditional technique for making transgenic animals, which entails injecting DNA into
cell nuclei.
These
cells, in turn, instruct factor - VIII —
specific immune
cells to become tolerant to the coagulation protein, resulting in suppression of misdirected antibody responses to the
replacement therapy — all without affecting the rest of the immune system.
«For the broad application of stem
cell - derived pituitary
cells in the future,
cell replacement therapy may need to be customized to the
specific needs of a given patient population,» Zimmer says.
Replacement tissue that avoids rejection by a patient's immune system is a step closer to the clinic, as researchers have created human embryonic stem
cells carrying the DNA of
specific adults.
iPSCs directed to differentiate into
specific cell types offer the possibility of a renewable source of
replacement cells and tissues to treat ailments, including Parkinson's disease, spinal cord injury, heart disease, diabetes, and arthritis.
Although traditional
cell replacement remains a central goal in applied stem
cell research, the derivation of patient -
specific iPS
cells might be equally useful for disease - related research.
Ultimately, we use all this information to establish innovative culture techniques for generating unlimited neural stem
cell sources for the derivation of
specific types of clinically relevant neuronal or glial
cells, for their use in disease modelling and drug discovery platforms, and towards refining their efficacy for future
cell replacement - based therapy.
One of the striking differences in outcome between our studies and work on oligodendrocyte and oligodendrocyte - precursor
replacement lies in the finding that differentiation of precursor
cells into a
specific astrocyte subtype prior to transplantation provides a much greater level of benefit than transplantation of the precursor
cells themselves.
A number of treatments exist, including enzyme
replacement therapy and hematopoietic stem
cell transplantation, but efficacy depends upon diagnosing the disease and its
specific form as early as possible.
As yet it is unknown whether iPS
cells can differentiate into functional
replacement cells for use in the treatment of progressive diseases
specific to the visual system.